Jane Armitage

• Safety and efficacy of statins - Authors' reply.

  Collins R. et al, (2017), Lancet, 389, 1099 - 1100

• Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.

  Hin H. et al, (2016), Osteoporos Int

• Interpretation of the evidence for the efficacy and safety of statin therapy.

  Collins R. et al, (2016), Lancet, 388, 2532 - 2561

• Lessons from the controversy over statins - Authors' reply.

  Armitage J. et al, (2016), Lancet, 388, 2237 - 2238

• The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs

  Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes

• Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).

  Aung T. et al, (2016), Trials, 17

• Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease.

  Herrington W. et al, (2016), Circ Res, 118, 535 - 546

• Management of residual risk after statin therapy.

  Reith C. and Armitage J., (2016), Atherosclerosis, 245, 161 - 170

• Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis

  Kitas GD. et al, (2015), ARTHRITIS & RHEUMATOLOGY, 67

• Lack of effect of higher dose vitamin D supplements on systolic blood pressure and arterial stiffness measure in older people after 12 months of treatment. Results of BEST-D trial

  Tomson J. et al, (2015), EUROPEAN HEART JOURNAL, 36, 801 - 801

• Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, SEARCH and HPS2-THRIVE studies

  Parish S. et al, (2015), EUROPEAN HEART JOURNAL, 36, 981 - 981

• TRIAL OF ATORVASTATIN FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH RA (TRACE RA): A RANDOMIZED TRIAL IN 2986 RA PATIENTS

  Kitas GD. et al, (2015), RHEUMATOLOGY, 54, 87 - 87

• Estimation of the optimum dose of vitamin D for disease prevention in older people: rationale, design and baseline characteristics of the BEST-D trial.

  Clarke R. et al, (2015), Maturitas, 80, 426 - 431

• Estimation of the optimum dose of vitamin D for disease prevention in older people: Rationale, design and baseline characteristics of the BEST-D trial

  Clarke R. et al, (2015), Maturitas, 80, 426 - 431

• Pharmacogenomics of statin therapy: any new insights in efficacy or safety?

  Hopewell JC. et al, (2014), Curr Opin Lipidol, 25, 438 - 445

• Adding niacin plus laropiprant to statins did not reduce vascular events and increased serious adverse events

  Landray MJ. et al, (2014), ANNALS OF INTERNAL MEDICINE, 161, JC8 - JC8

• Niacin for reduction of cardiovascular risk.

  Landray MJ. et al, (2014), N Engl J Med, 371, 1943 - 1944

• Misrepresentation of statin safety evidence.

  Armitage J. et al, (2014), Lancet, 384, 1263 - 1264

• Phenotype standardization for statin-induced myotoxicity.

  Alfirevic A. et al, (2014), Clin Pharmacol Ther, 96, 470 - 476

• Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals.

  Clarke R. et al, (2014), Am J Clin Nutr, 100, 657 - 666

• Effects of extended-release niacin with laropiprant in high-risk patients.

  HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212

• Pharmacogenomics of statin therapy: Any new insights in efficacy or safety?

  Hopewell JC. et al, (2014), Current Opinion in Lipidology, 25, 438 - 445

• News from the European atherosclerosis society congress

  Armitage J., (2014), British Journal of Cardiology, 21

• A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.

  Mangravite LM. et al, (2013), Nature, 502, 377 - 380

• Reply: To PMID 22334567.

  Antoniades CG. and Wendon J., (2013), Hepatology, 58, 1187 - 1188

• Vitamin D and risk of death from vascular and non-vascular causes in the Whitehall study and meta-analyses of 12,000 deaths.

  Tomson J. et al, (2013), Eur Heart J, 34, 1365 - 1374

• HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.

  HPS2-THRIVE Collaborative Group None., (2013), Eur Heart J, 34, 1279 - 1291

• Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.

  Hopewell JC. et al, (2013), Eur Heart J, 34, 982 - 992

• Does the benefit from statin therapy extend beyond 5 years?

  Bulbulia R. and Armitage J., (2013), Curr Atheroscler Rep, 15

• Does the benefit from statin therapy extend beyond 5 years?

  Bulbulia R. and Armitage J., (2013), Current atherosclerosis reports, 15

• Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals.

  Vollset SE. et al, (2013), Lancet

• [ACEI/ARB use among high risk patients with coronary heart disease in China: a cross-sectional study].

  Liu JM. et al, (2013), Zhonghua Xin Xue Guan Bing Za Zhi, 41, 18 - 22

• Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.

  Li J. et al, (2012), Chin Med J (Engl), 125, 4361 - 4367

• LDL cholesterol targets--how low to go?

  Bulbulia R. and Armitage J., (2012), Curr Opin Lipidol, 23, 265 - 270

• Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE

  Hopewell JC. et al, (2012), EUROPEAN HEART JOURNAL, 33, 445 - 445

• Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.

  Parish S. et al, (2012), Circulation, 125, 2469 - 2478

• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  Mihaylova B. et al, (2012), Lancet

• Safety of long-term simvastatin discontinuation Reply

  Bulbulia R. et al, (2012), LANCET, 379, 1704 - 1704

• Underuse of statins in patients with atherosclerotic ischemic stroke in China.

  Li X. et al, (2012), Chin Med J (Engl), 125, 1703 - 1707

• Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

  Armitage J. et al, (2012), Ecancermedicalscience, 6

• Recruiting patients cost-effectively by mail.

  Aung T. et al, (2011), Trials, 12 Suppl 1

• Investigating strategies to improve attendance at screening visits in a randomized trial.

  Chen F. et al, (2011), Trials, 12 Suppl 1

• Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.

  Heart Protection Study Collaborative Group None. et al, (2011), Lancet, 378, 2013 - 2020

• Vitamin D and Risk of Cardiovascular and Non-Cardiovascular Mortality: A Prospective Cohort Study and Meta-Analysis

  Emberson JR. et al, (2011), CIRCULATION, 124

• Randomised trials remain essential and are not overrated

  Armitage J., (2011), Journal of the Royal College of Physicians of Edinburgh, 41, 129 - 131

• Randomised controlled trials: Important but overrated?

  Boylan JF. et al, (2011), Journal of the Royal College of Physicians of Edinburgh, 41

• Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study

  Hopewell JC. et al, (2011), EUROPEAN HEART JOURNAL, 32, 154 - 155

• The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.

  Baigent C. et al, (2011), Lancet, 377, 2181 - 2192

• C-reactive protein in the Heart Protection Study - Authors' reply

  Emberson J. et al, (2011), The Lancet, 377, 1918 - 1919

• No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

  Hopewell JC. et al, (2011), J Am Coll Cardiol, 57, 2000 - 2007

• Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial.

  de Silva HA. et al, (2011), PLoS Med, 8

• A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.

  Coronary Artery Disease (C4D) Genetics Consortium None., (2011), Nat Genet, 43, 339 - 344

• C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study

  Emberson J. et al, (2011), Lancet, 377, 469 - 476

• Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.

  Hopewell JC. et al, (2011), Circ Cardiovasc Genet, 4, 68 - 73

• Clinical trials of lipid-modifying agents: Design considerations

  Bowman L. et al, (2011), Clinical Lipidology, 6, 109 - 116

• Survey of treatment of hypertension among patients with ischemic stroke

  Li J. et al, (2011), Chin J Hypert, 19, 246 - 250

• Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study

  Hopewell JC. et al, (2010), CIRCULATION, 122

• Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), Lancet, 376, 1658 - 1669

• Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

  Baigent C. et al, (2010), AMERICAN HEART JOURNAL, 160, 785 - U28

• In reply

  Armitage J. et al, (2010), JAMA - Journal of the American Medical Association, 304, 1783 - 1784

• Effects of Folic Acid Plus Vitamin B-12 vs Placebo in Myocardial Infarction Survivors Reply

  Armitage J. et al, (2010), JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 304, 1783 - 1784

• Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals.

  Clarke R. et al, (2010), Arch Intern Med, 170, 1622 - 1631

• Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality

  Parish S. et al, (2010), JOURNAL OF INTERNAL MEDICINE, 268, 348 - 358

• Risk Factor Control among Chinese High-Risk Patients with Diabetes

  Chen F. et al, (2010), CIRCULATION, 122, E84 - E84

• Low Use of Statins among High-risk Patients in China

  Jiang L. et al, (2010), CIRCULATION, 122, E270 - E270

• Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494

• How the NHS research governance procedures could be modified to greatly strengthen clinical research.

  Haynes R. et al, (2010), Clin Med (Lond), 10, 127 - 129

• Survey of statin usage in 4429 diabetic patients with atherosclerostic cardiovascular disease in China

  Jiang L. et al, (2010), Chin J Cardiovasc Med, 15, 264 - 268

• Cross-sectional study of statin use among high-risk patients with coronary heart disease in China

  Li J. et al, (2010), Chin Circ J, 25, 348 - 351

• A cross-sectional study on the use of statin among patients with atherosclerotic ischemic stroke in China

  Jiang L. et al, (2010), Chin J Epidemiol, 31, 925 - 928

• Greater absolute reductions in LDL cholesterol should yield greater proportional reductions in risk of cardiovascular disease.

  Clarke R. and Armitage J., (2009), J Intern Med, 266, 499 - 501

• Aspirin for primary prevention of vascular disease in people with diabetes.

  Haynes R. et al, (2009), BMJ, 339

• No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study

  Hopewell JC. et al, (2009), CIRCULATION, 120, S606 - S606

• Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials

  Rahimi K. et al, (2009), EUROPEAN HEART JOURNAL, 30, 591 - 591

• Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials

  Rahimi K. et al, (2009), EUROPEAN HEART JOURNAL, 30, 450 - 451

• Plasma phospholipid fatty acids and CHD in older men: Whitehall study of London civil servants.

  Clarke R. et al, (2009), Br J Nutr, 102, 279 - 284

• Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.

  MRC/BHF Heart Protection Study Collaborative Group None. et al, (2009), BMC Clin Pharmacol, 9

• Statin cost-effectiveness in the United States for people at different vascular risk levels.

  Heart Protection Study Collaborative Group None., (2009), Circ Cardiovasc Qual Outcomes, 2, 65 - 72

• Therapeutic Strategies in Lipid Disorders

  Armitage J. and Bowman LJ., (2009), 15 - 28

• Estimated 10-year cardiovascular risk in a British population: results of a national screening project.

  Neil HA. et al, (2008), Int J Clin Pract, 62, 1322 - 1331

• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  SEARCH Collaborative Group None. et al, (2008), N Engl J Med, 359, 789 - 799

• Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.

  Armitage J., (2008), Heart, 94, 643 - 645

• Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply

  Bulbulia R. et al, (2008), JOURNAL OF VASCULAR SURGERY, 47, 901 - 901

• Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

  Cholesterol Treatment Trialists' (CTT) Collaborators None. et al, (2008), Lancet, 371, 117 - 125

• The impact of privacy and confidentiality laws on the conduct of clinical trials.

  Armitage J. et al, (2008), Clin Trials, 5, 70 - 74

• The safety of statins in clinical practice.

  Armitage J., (2007), Lancet, 370, 1781 - 1790

• Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.

  SEARCH Study Collaborative Group None. et al, (2007), Am Heart J, 154, 815 - 823.e6

• Fluvastatin for reduction of cardiovascular risk in patients with moderate to severe renal insufficiency.

  Haynes R. and Armitage J., (2007), Nat Clin Pract Nephrol, 3, 530 - 531

• Estimated 10-year cardiovascular risk in a British population: Results of a national screening project

  Neil HAW. et al, (2007), ATHEROSCLEROSIS, 194, 281 - 281

• Cholesterol fractions and apolipoprotiens are strong predictors of heart disease mortality in older men

  Clarke R. et al, (2007), EUROPEAN HEART JOURNAL, 28, 87 - 87

• Cholesterol fractions and apolipoproteins as risk factors for heart disease mortality in older men.

  Clarke R. et al, (2007), Arch Intern Med, 167, 1373 - 1378

• MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS

  Bulbulia R. et al, (2007), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49, 393A - 393A

• N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.

  Heart Protection Study Collaborative Group None. et al, (2007), J Am Coll Cardiol, 49, 311 - 319

• Homocysteine-lowering trials for prevention of vascular disease: protocol for a collaborative meta-analysis.

  Clarke R. et al, (2007), Clin Chem Lab Med, 45, 1575 - 1581

• Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia.

  Clarke R. et al, (2007), Curr Opin Clin Nutr Metab Care, 10, 32 - 39

• Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.

  Heart Protection Study Collaborative None. et al, (2006), BMJ, 333

• The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

  Landray M. et al, (2006), Am J Kidney Dis, 47, 385 - 395

• Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.

  B-Vitamin Treatment Trialists' Collaboration None., (2006), Am Heart J, 151, 282 - 287

• N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study

  Emberson J. et al, (2005), CIRCULATION, 112, U867 - U867

• Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial

  Mihaylova B. et al, (2005), CIRCULATION, 112, U900 - U901

• N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study

  Emberson J. et al, (2005), EUROPEAN HEART JOURNAL, 26, 337 - 337

• Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.

  Mihaylova B. et al, (2005), Lancet, 365, 1779 - 1785

• The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393].

  Heart Protection Study Collaborative Group None., (2005), BMC Med, 3

• First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.

  Baigent C. et al, (2005), Am J Kidney Dis, 45, 473 - 484

• Cardiovascular outcomes among participants with diabetes in the recent large statin trials.

  Armitage J. and Bowman L., (2004), Curr Opin Lipidol, 15, 439 - 446

• New analyses of Heart Protection Study.

  Lemiengre M. et al, (2004), Lancet, 363, 1827 - 1828

• New analyses of Heart Protection Study - Reply

  Collins R. et al, (2004), LANCET, 363, 1828 - 1828

• Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

  Collins R. et al, (2004), Lancet, 363, 757 - 767

• Economic evaluation of the Heart Protection Study

  Briggs A. et al, (2003), CIRCULATION, 108, 776 - 776

• Comments on the MRC/BHF Heart Protection Study - Authors' reply

  Collins R. et al, (2003), LANCET, 362, 744 - 745

• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

  Collins R. et al, (2003), Lancet, 361, 2005 - 2016

• Heart Protection Study.

  Metcalfe RS. et al, (2003), Lancet, 361

• Heart Protection Study - Reply

  Collins R. et al, (2003), LANCET, 361, 529 - 530

• MRC/BHF Heart Protection Study.

  Vaughan CJ. et al, (2002), Lancet, 360, 1780 - 1781

• MRC/BHF Heart Protection Study - Reply

  Collins R. et al, (2002), LANCET, 360, 1783 - 1784

• High-risk elderly patients PROSPER from cholesterol-lowering therapy.

  Collins R. and Armitage J., (2002), Lancet, 360, 1618 - 1619

• Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk.

  Bowman L. and Armitage J., (2002), Semin Vasc Med, 2, 383 - 389

• Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomised trials.

  Clarke R. and Armitage J., (2002), Cardiovasc Drugs Ther, 16, 411 - 415

• MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial

  Collins R. et al, (2002), LANCET, 360, 23 - 33

• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22

• Randomized trial of cholesterol-lowering, and of antioxidant vitamins, in 6,000 people with diabetes mellitus

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 245A - 245A

• Randomized trial of cholesterol-lowering and antioxidant vitamins in 5,000 women at high-risk of coronary heart disease

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 245A - 245A

• Randomized trial of cholesterol-lowering and antioxidant vitamins in 7,000 high-risk individuals with LDL cholesterol below 120 mg/dl

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 245A - 245A

• Effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on the risk of stroke

  Collins R. et al, (2002), JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39, 246A - 246A

• The MRC/BHF Heart Protection Study: preliminary results.

  Collins R. et al, (2002), Int J Clin Pract, 56, 53 - 56

• Status report of lipid-lowering trials in diabetes.

  Betteridge DJ. et al, (2000), Curr Opin Lipidol, 11, 621 - 626

• Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.

  Armitage J. and Collins R., (2000), Heart, 84, 357 - 360

• Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.

  Clarke R. and Armitage J., (2000), Semin Thromb Hemost, 26, 341 - 348

• Lipid-lowering trials in diabetes

  Armitage J., (1999), EUROPEAN HEART JOURNAL SUPPLEMENTS, 1, M13 - M17

• MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

  Meade T. et al, (1999), European Heart Journal, 20, 725 - 741

• Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects (vol 316, pg 1213, 1998)

  Tang JL. et al, (1998), BRITISH MEDICAL JOURNAL, 316, 1605 - 1605

• Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects.

  Tang JL. et al, (1998), BMJ, 316, 1213 - 1220

• Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.

  Mitropoulos KA. et al, (1997), Eur Heart J, 18, 235 - 241

• Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.

  Keech AC. et al, (1996), Br J Clin Pharmacol, 42, 483 - 490

• Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration

  Wardle J. et al, (1996), British Medical Journal, 313, 75 - 78

• Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

  Harris ML. et al, (1995), Br J Ophthalmol, 79, 996 - 1002

• PROTOCOL FOR A PROSPECTIVE COLLABORATIVE OVERVIEW OF ALL CURRENT AND PLANNED RANDOMIZED TRIALS OF CHOLESTEROL TREATMENT REGIMENS

  DOWNS J. et al, (1995), AMERICAN JOURNAL OF CARDIOLOGY, 75, 1130 - 1134

• Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study.

  Keech A. et al, (1994), Eur Heart J, 15, 255 - 269

• Investigation of the tendency to wheeze in pollen sensitive patients.

  Armitage JM. et al, (1992), Clin Exp Allergy, 22, 916 - 922

• Ear involvement in the yellow nail syndrome.

  Armitage JM. et al, (1990), Chest, 98, 1534 - 1535

• Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: Results from the Study of Heart and Renal Protection

  Reith CA. et al, BMC Nephrology

Key Publications

• Effects of extended-release niacin with laropiprant in high-risk patients.

  HPS2-THRIVE Collaborative Group None. et al, (2014), N Engl J Med, 371, 203 - 212

• Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

  Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group None. et al, (2010), JAMA, 303, 2486 - 2494

• The safety of statins in clinical practice.

  Armitage J., (2007), Lancet, 370, 1781 - 1790

• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  Heart Protection Study Collaborative Group None., (2002), Lancet, 360, 7 - 22

Recent Publications

• Safety and efficacy of statins - Authors' reply.

  Collins R. et al, (2017), Lancet, 389, 1099 - 1100

• Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.

  Hin H. et al, (2016), Osteoporos Int

• Interpretation of the evidence for the efficacy and safety of statin therapy.

  Collins R. et al, (2016), Lancet, 388, 2532 - 2561

• Lessons from the controversy over statins - Authors' reply.

  Armitage J. et al, (2016), Lancet, 388, 2237 - 2238

• The Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin with Laropiprant on Health and Healthcare Costs

  Mihaylova BN. et al, (2016), Circulation: Cardiovascular Quality and Outcomes